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Combined modality adjuvant therapy for high-risk 
endometrial cancer
The incidence of endometrial cancer has steadily 
increased over the past decade, with 320 000 new cases 
reported worldwide in 2012.1 Endometrial cancer is the 
ﬁ fth most common cancer in women, and incidence is 
projected to increase2 because of an increased prevalence 
of obesity and an ageing population. Although most 
patients present with early-stage low-risk disease, a rise 
in incidence is expected to lead to an increasing number 
of high-risk cases at presentation. This heterogenous 
group of tumours is characterised by higher grade 
and stage, deep myometrial invasion, lymph-vascular 
space invasion, or non-endometrioid histologies, 
such as serous or clear-cell cancers. Despite optimum 
surgical treatments, these tumours have an increased 
risk of local and distant recurrences and are therefore 
considered targets for adjuvant therapy. External beam 
radiotherapy showed a signiﬁ cant reduction in the risk 
of local relapse compared with observation, but did 
not show a signiﬁ cant survival advantage in a high-risk 
subgroup meta-analysis.3 
Although endometrial cancers are generally radio-
sensitive and local relapse might be prevented by 
radiotherapy, many patients with high-risk disease 
still have distant metastatic relapses. Therefore, a 
systemic treatment with adjuvant chemotherapy was 
proposed as a solution, with or without radiotherapy. 
Randall and colleagues4 previously randomly assigned 
396 patients with stage III–IV endometrial carcinoma 
to adjuvant chemotherapy versus whole-abdominal 
irradiation and showed a survival beneﬁ t for adjuvant 
chemotherapy. Hogberg and colleagues5 pooled 
the data of the NSGO-EC-95016 and the MaNGO 
ILIADE-III trials and reported on 534 patients randomly 
assigned to either radiotherapy or combined sequential 
radiotherapy and chemotherapy in the adjuvant setting. 
The NSGO-EC-9501 study and both studies combined 
showed a signiﬁ cant improvement in progression-free 
and cancer-speciﬁ c survival in the combined treatment 
group.
In The Lancet Oncology, Stephanie de Boer and 
colleagues7 report the ﬁ rst results of the multicentre 
PORTEC-3 randomised trial, focusing on toxicity and 
2-year quality in those who received radiotherapy and 
those who received chemotherapy plus radiotherapy. 
Overall, 686 women were randomly assigned 
(330 to receive chemotherapy plus radiotherapy 
and 330 to receive radiotherapy alone). Baseline 
characteristics in both groups were well balanced, 
although comorbidity rates were higher in the 
combined therapy group. Toxicity and quality of life data 
were available for 660 patients and showed a higher 
incidence of severe adverse events and patient-reported 
symptoms in the combined group with radiotherapy 
and chemotherapy, mainly related to the well known 
side-eﬀ ects of paclitaxel and carboplatin therapy. 
Most patients with adverse events recovered quickly 
after the end of the treatment, although peripheral 
sensory neuropathy was deemed troublesome by a 
quarter of all patients in the combined group at 2 years. 
Although the toxicities of combined treatment were 
shown to be manageable, whether this investment of 
adding chemotherapy will be rewarded by an improved 
outcome in the long term remains unclear. The fact that 
a toxicity and quality of life analysis were included as 
secondary endpoints in the trial design, which was not 
the case for the combined NSGO-EC-9501 and MaNGO 
ILIADE-III trials,5 is a merit to the researchers. However, 
the trial had a few limitations. More than a third of all 
patients in both groups did not receive a complete 
staging surgery, including lymphadenectomy, because 
lymphadenectomy was optional. This could lead to 
the underestimation of stage IIIC disease in which 
the addition of chemotherapy has been shown to 
increase survival.4,5 Although two large randomised 
trials8,9 could not establish the value of a systematic 
lymphadenectomy in stage I endometrial cancer, the 
number of high-risk cases in these studies was rather 
small. To establish the value of a pelvic and para-aortic 
lymphadenectomy in high-risk endometrial cancer, 
the STATEC study (Selective Targeting of Adjuvant 
Therapy for Endometrial Cancer, NCT02566811) 
is in preparation at present. Furthermore, if future 
results of the PORTEC-3 trial conﬁ rm the progression-
free and cancer-speciﬁ c survival beneﬁ t for the 
combined treatment group observed in the combined 
NSGO-EC-9501 and MaNGO ILIADE-III trials, the 
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question remains of how much radiotherapy adds to 
the observed eﬀ ect of adjuvant chemotherapy. This will 
be addressed by the results of the ongoing GOG-258 
trial (NCT00942357), studying the same combined 
chemoradiotherapy regimen as in PORTEC-3.
Overall, the study by de Boer and colleagues clearly 
shows the feasibility of combined modality therapy 
for high-risk endometrial cancer. If the study shows 
a survival beneﬁ t for the adjuvant chemotherapy 
plus radiotherapy, combined therapy is expected to 
become the standard-of-care for high-risk endometrial 
cancer. With the present data on toxicity and quality 
of life, the (yet to be determined) survival beneﬁ ts of 
chemotherapy can be weighed against the adverse 
events and quality of life measures reported in this 
study, which will improve the adjuvant therapy for 
women with high-risk endometrial cancer.
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